VANELTIX PHARMA, INC.

Profile

Company Names

VANELTIX PHARMA, INC.
URIGEN PHARMACEUTICALS, INC.

Addresses

317 GEORGE STREET, SUITE 400, NEW BRUNSWICK, NJ 08901

305 E. HIGH ST., UNIT 7, BOUND BROOK, NJ 08805

675 HIGHWAY ONE, SUITE B-206, NORTH BRUNSWICK, NJ 08902

675 HIGHWAY ONE B-206, NORTH BRUNSWICK, NJ 08902

501 SILVERSIDE ROAD PMB#95, WILMINGTON, DE 19809

Phone Numbers

732-354-3217
732-369-5911
732-640-0160
(925) 280-2861

 

Entity Type:

CORPORATION

Industry:

PHARMACEUTICALS

Year Incorporated:

> 5 years ago

State Incorporated:

DELAWARE

Total Amount Raised:

$7,054,843.00

Number of Funding Rounds:

6
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
6
2023-12-12 
$1,000,000.00 
$5,000,000.00 
$4,000,000.00 
Equity 
5
2020-10-21 
$3,021,843.00 
$3,021,843.00 
$0.00 
Equity 
4
2018-01-26 
$1,377,000.00 
$1,377,000.00 
$0.00 
Equity 
3
2017-03-30 
$500,000.00 
$15,000,000.00 
$14,500,000.00 
Debt 
2
2015-07-01 
$300,000.00 
$12,365,759.00 
$12,065,759.00 
Equity, Debt 
1
2013-07-03 
$856,000.00 
$856,000.00 
$0.00 
Debt 
People
First Name
Middle Name
Last Name
Titles
Related Companies
CARLO 
 
DI FONZO 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.   |  VANELTIX PHARMA, INC.
ROBERT 
LOWELL 
EVANS 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.   |  VANELTIX PHARMA, INC.
MICHAEL 
 
GOLDBERG 
DIRECTOR
IRHYTHM TECHNOLOGIES INC   |  MDV IX LP   |  CRESCENDO BIOSCIENCE, INC.   |  CORVENTIS INC   |  CIVICSOLAR, INC   |  CARDIODX INC   |  ALLIQUA, INC.   |  CORNOVA INC   |  DNANEXUS, INC.   |  COGNOTION, INC.   |  URIGEN PHARMACEUTICALS, INC.   |  MEDITOPE BIOSCIENCES, INC.   |  CAREDX, INC.   |  YOR LABS, INC.   |  STIMIT CORP   |  COUNSLR, INC.   |  MAMS HOLDCO LLC
ABE 
 
HAHN 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.
A. 
LUC 
MAASDORP 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.
MICHAEL 
 
NORDLICHT 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.   |  MDWERKS, INC.
C. 
LOWELL 
PARSONS 
DIRECTOR
URIGEN PHARMACEUTICALS, INC.   |  VANELTIX PHARMA, INC.
MARK 
J. 
ROSENBLUM 
EXECUTIVE OFFICER
ADVAXIS, INC.   |  URIGEN PHARMACEUTICALS, INC.   |  SALARIUS PHARMACEUTICALS, INC.
DAN 
 
VICKERY 
EXECUTIVE OFFICER, DIRECTOR
URIGEN PHARMACEUTICALS, INC.
DANIEL 
 
VICKERY 
EXECUTIVE OFFICER, DIRECTOR
VANELTIX PHARMA, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2024-01-24
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2023-12-12 
2020-11-20
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2020-10-21 
2018-02-07
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2018-01-26 
2017-04-13
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2017-03-30 
2015-07-14
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity, Debt 
2015-07-01 
2013-10-04
D/A
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2013-07-03 
2013-07-19
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Debt 
2013-07-03 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
NONE
NONE